Do you want to read an article? Please log in or register.
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Inflammatory Bowel Disease
Related content
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Lancet Gastroenterol Hepatol.
Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO
doi: 10.1016/S2468-1253
Inflammatory Bowel Disease
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Lancet Gastroenterol Hepatol.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group
doi: 10.1016/S2468-1253(19)30012-3.
Inflammatory Bowel Disease
Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study
BMC Gastroenterol.
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO, Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators., European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP)
doi: 10.1186/s12876-019-0992-2.
Inflammatory Bowel Disease
Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3
Inflamm Bowel Dis.
Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T
doi: 10.1093/ibd/izy384.
Inflammatory Bowel Disease
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
J Crohns Colitis
Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ
doi: 10.1093/ecco-jcc/jjab133
Inflammatory Bowel Disease
Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study
United European Gastroenterol J.
Tai FWD, Ellul P, Elosua A, Fernandez-Urien I, Tontini GE, Elli L, Eliakim R, Kopylov U, Koo S, Parker C, Panter S, Sidhu R, McAlindon M
doi: 10.1177/2050640620948664.
COMMENTED
Inflammatory Bowel Disease
Long-Term Efficacy And Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
J Crohns Colitis
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G
doi: 10.1093/ecco-jcc/jjab012
Inflammatory Bowel Disease
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
J Crohns Colitis
Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR
doi: 10.1093/ecco-jcc/jjab093
Inflammatory Bowel Disease
Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial
Gut.
Levine A, Kori M, Kierkus J, Sigall Boneh R, Sladek M, Escher JC, Wine E, Yerushalmi B, Amil Dias J, Shaoul R, Veereman Wauters G, Boaz M, Abitbol G, Bousvaros A, Turner D
doi: 10.1136/gutjnl-2017-315199.